IL-2 Discovery 50 Years On: Impact on Retrovirology and Cancer Treatment

A new perspective published in *Science* revisits a landmark discovery that has shaped modern medicine. In 1976, Robert C. Gallo, MD, and colleagues isolated a human T‑cell growth factor that would later be identified as interleukin‑2 (IL‑2). The finding not only established the field of human retrovirology but also deepened knowledge of the human immune system and laid the groundwork for subsequent breakthroughs in cancer therapy.

The article traces how Gallo’s work on IL‑2 revealed the first evidence that viruses could manipulate immune cells, a concept that spurred the rapid expansion of retrovirus research. By demonstrating that IL‑2 could stimulate the proliferation of T lymphocytes, scientists gained a powerful tool for studying immune responses and, eventually, for developing IL‑2‑based immunotherapies. These therapies have since become a cornerstone of treatments for melanoma, renal cell carcinoma, and other malignancies, illustrating the long‑term impact of the original discovery.

In concluding, the *Science* perspective underscores the enduring legacy of Gallo’s 1976 breakthrough. It highlights how a single molecular insight catalyzed progress across virology, immunology, and oncology, and it reminds researchers that foundational discoveries can reverberate for decades, driving innovation and saving lives.